Findings in Antivirals Reported from Institute of Chemical Technology (Efavirenz Loaded Nanostructured Lipid Carriers for Efficient and Prolonged Viral Inhibition in HIV-lnfected Macrophages)

摘要

2021 SEP 21 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - Researchers detail new data in antivirals. According to news reporting out of the Institute of Chemical Technology by NewsRx editors, research stated, "The clinical outcome of anti-HIV therapy is poor due to the inherent fallouts ofanti-HIV therapy. It is further worsened due to the presence of viral reservoirs in immune cellslike the macrophages." The news reporters obtained a quote from the research from Institute of Chemical Technology: "An ideal anti-HIV therapy must reach, deliver the drug and exert itsaction inside macrophages. To address this, we developed novel cationic nanostructured lipidcarriers of efavirenz (cationic EFV-NLC). The developed cationic EFV NLCs were evaluated for particle size, zeta potential,encapsulation efficiency, in-vitro drug release, DSC, XRD, TEM, cytotoxicity, cellular uptakestudies and anti-HIV efficacy in a monocyte-derived macrophage cell line (THP-1). Cationic EFV-NLCs showed high encapsulation efficiency (90.54 ± 1.7%), uniform particle size distribution (PDI 0.3-0.5 range) and high colloidal stability with positive zetapotential (+23.86 ± 0.49 mV). DSC and XRD studies confirmed the encapsulation of EFVwithin NLCs.